Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet (London, England). 2018 Mar 31;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018;16(1):47–60.
   PubMed Web of Science ®Google Scholar
• Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza a (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605–2615.
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th century. Emerging Infect Dis. 2006;12(1):9–14.
   PubMed Web of Science ®Google Scholar
• CDC Seasonal Flu Vaccine Effectiveness Studies [Internet]. Georgia: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD); [updated 2022 Aug 31; cited 2022 Dec 23]; Available from: https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html.
   Google Scholar
• Wu NC, Wilson IA. Influenza hemagglutinin structures and antibody recognition. Cold Spring Harbor Perspect Med. 2020 Aug 3;10(8):a038778.
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP + M1. Clin Infectious Diseases. 2011 Jan 1;52(1):1–7.
   PubMed Web of Science ®Google Scholar
• Ong HK, Yong CY, Tan WS, et al. An influenza a vaccine based on the extracellular domain of matrix 2 protein protects BALB/C mice against H1N1 and H3N2. Vaccines (Basel). 2019 Aug 19;7(3):91.
   PubMed Web of Science ®Google Scholar
• Darricarrère N, Qiu Y, Kanekiyo M, et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci Transl Med. 2021;13(583):eabe5449.
   PubMed Web of Science ®Google Scholar
• Fadlallah GM, Ma F, Zhang Z, et al. Vaccination with consensus H7 elicits broadly reactive and protective antibodies against Eurasian and North American lineage H7 viruses. Vaccines (Basel). 2020;8(1):143.
   PubMed Web of Science ®Google Scholar
• Reneer ZB, Skarlupka AL, Jamieson PJ, et al. Broadly reactive H2 hemagglutinin vaccines elicit cross-reactive antibodies in ferrets preimmune to seasonal influenza a viruses. mSphere. 2021 Mar 10;6(2):e00052-21.
   PubMed Web of Science ®Google Scholar
• Sautto GA, Kirchenbaum GA, Ecker JW, et al. Elicitation of broadly protective antibodies following infection with influenza viruses expressing H1N1 computationally optimized broadly reactive hemagglutinin antigens. Immuno Horizons. 2018;2(7):226–237.
   Google Scholar
• Kim YH, Hong KJ, Kim H, et al. Influenza vaccines: past, present, and future. Rev Med Virol. 2022 Jan;32(1):e2243.
   PubMed Web of Science ®Google Scholar
• Armbruster N, Jasny E, Petsch B. Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies. Vaccines (Basel). 2019;7(4):132.
   PubMed Web of Science ®Google Scholar
• Gómez CE, Perdiguero B, Usero L, et al. Enhancement of the HIV-1-specific immune response induced by an mRNA vaccine through boosting with a poxvirus MVA vector expressing the same antigen. Vaccines (Basel). 2021;9(9):959.
   PubMed Web of Science ®Google Scholar
• Espeseth AS, Cejas PJ, Citron MP, et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines. 2020;5(1):16.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114–1125.e1110.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Shartouny JR, Lowen AC. Message in a bottle: mRNA vaccination for influenza. J Gen Virol. 2022 Jul;103(7):001765.
   PubMed Web of Science ®Google Scholar
• Kowalzik F, Schreiner D, Jensen C, et al. mRNA-based vaccines. Vaccines (Basel). 2021 Apr 15;9(4):390.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
   PubMed Web of Science ®Google Scholar
• Liu MA. Immunologic basis of vaccine vectors. Immunity. 2010;33(4):504–515.
   PubMed Web of Science ®Google Scholar
• Magini D, Giovani C, Mangiavacchi S, et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PloS One. 2016;11(8):e0161193.
   PubMed Web of Science ®Google Scholar
• Freyn AW, da Silva R, Rosado J, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther: J Am Soc Gene Therapy. 2020;28(7):1569–1584.
   PubMed Web of Science ®Google Scholar
• Hajam IA, Senevirathne A, Hewawaduge C, et al. Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens. Vet. Res. 2020;51(1):37.
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283.e1216.
   PubMed Web of Science ®Google Scholar
• Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.
   PubMed Web of Science ®Google Scholar
• Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines. 2010;9(12):1423–1439.
   PubMed Web of Science ®Google Scholar
• Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (New York, NY). 1987 May 22;236(4804):944–947.
   Google Scholar
• Ping X, Hu W, Xiong R, et al. Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence. Vaccine. 2018;36(32 Pt B):4837–4845.
   PubMed Web of Science ®Google Scholar
• Starostina EV, Sharabrin SV, Antropov DN, et al. Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens. Vaccines (Basel). 2021;9(5):452.
   PubMed Web of Science ®Google Scholar
• Buschmann MD, Carrasco MJ, Alishetty S, et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). 2021;9(1):65.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Qi Y, Wang M, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel). 2020;8(1):123.
   PubMed Web of Science ®Google Scholar
• Alameh MG, Tombácz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–2892.e2877.
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Eisinger RW, et al. The pathway to a universal influenza vaccine. Immunity. 2017;47(4):599–603.
   PubMed Web of Science ®Google Scholar